Home › PBT2 Recommended For Orphan Designation In Europe
 

Keywords :   


PBT2 Recommended For Orphan Designation In Europe

2015-04-29 03:49:41| drugdiscoveryonline Home Page

Prana Biotechnology is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC)

Tags: europe recommended designation orphan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Lawsuit over FDA's regulatory approval process for carbadox dismissed
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Tropical Depression Fourteen-E Graphics
More »